{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-021937","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.700907+00:00","generated_at":"2026-06-02T05:34:51.578122+00:00","sec_items":["1.01","2.01","5.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"X4 Pharma sells PRV for $105M, draws $20M from Hercules; cash runway extended into late 2025","bullets":["Sold Rare Pediatric Disease Priority Review Voucher for $105M cash; buyer undisclosed.","Drew additional $20M tranche under existing Hercules Capital term loan facility (interest-only until July 2027).","Combined with $82M cash at March 31, 2024, total pro-forma cash ~$207M; runway extended into late 2025, excluding XOLREMDI sales.","CFO Adam Mostafa awarded $102K discretionary bonus for efforts in securing the PRV sale.","XOLREMDI (mavorixafor) received FDA approval in April 2024 for WHIM syndrome; Phase 3 trial in chronic neutropenia planned this quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-021937","json":"https://secwatch.observer/filing/0001628280-24-021937.json","markdown":"https://secwatch.observer/filing/0001628280-24-021937.md","text":"https://secwatch.observer/filing/0001628280-24-021937.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024021937/0001628280-24-021937-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024021937/xfor-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:34:51.578122+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2b5bd9556d047bd1b3892042429be6c586f09106","claim":"X4 Pharmaceuticals, Inc completed a disposition for $105.0 million (closed 2024-05-08).","evidence_excerpt":"On May 8, 2024, X4 Pharmaceuticals, Inc. (the “Company”), entered into an asset purchase agreement (the “Asset Purchase Agreement”) to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”) for a lump sum payment of $105.0 million, payable in cash upon the closing of the sale, which occurred simultaneously with the parties entering into the Asset Purchase Agreement.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024021937/0001628280-24-021937-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Consideration","value":"$105.0 million"},{"label":"Closing","value":"2024-05-08"}]},{"claim_id":"9e18927b4b2ab31c97e971350c7879ca4e31a4d8","claim":"X4 Pharmaceuticals, Inc entered into Asset Purchase Agreement with not specified valued at $105,000,000 (effective 2024-05-08).","evidence_excerpt":"On May 8, 2024, X4 Pharmaceuticals, Inc. (the “Company”), entered into an asset purchase agreement (the “Asset Purchase Agreement”) to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”) for a lump sum payment of $105.0 million, payable in cash upon the closing of the sale, which occurred simultaneously with the parties entering into the Asset Purchase Agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024021937/0001628280-24-021937-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"not specified"},{"label":"Value","value":"$105,000,000"},{"label":"Effective","value":"2024-05-08"}]}],"comparable_filings":[{"accession":"0001193125-26-251791","ticker":"KRMN","company_name":"Karman Holdings Inc.","filed_at":"2026-06-01T21:28:29+00:00","headline":"Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds","event_type":"other_material","sec_items":["1.01","7.01","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 7.01, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251791","json":"https://secwatch.observer/filing/0001193125-26-251791.json","markdown":"https://secwatch.observer/filing/0001193125-26-251791.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/0001193125-26-251791-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/d117104d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 8, 2024, X4 Pharmaceuticals, Inc. (the “Company”), entered into an asset purchase agreement (the “Asset Purchase Agreement”) to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”) for a lump sum payment of $105.0 million, payable in cash upon the closing of the sale, which occurred simultaneously with the parties entering into the Asset Purchase Agreement.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024021937/0001628280-24-021937-index.htm","comparable_excerpt":"On May 28, 2026, Karman Holdings Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with the persons named in Schedule II thereto (the “Selling Stockholders”) and Citigroup Global Markets Inc. and Evercore Group L.L.C., as the underwriters (the “Underwriters”), pursuant to which the Selling Stockholders agreed to sell 14,000,000 shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”) at a public offering price of $61.00 per share (the “Offering Price”), less underwriting discounts and commissions (the “Offering”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/0001193125-26-251791-index.htm"}},{"accession":"0001185185-26-002273","ticker":"DGAC","company_name":"DISCIPLINED GROWTH ACQUISITION Corp","filed_at":"2026-06-01T20:15:34+00:00","headline":"Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 5.02, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-26-002273","json":"https://secwatch.observer/filing/0001185185-26-002273.json","markdown":"https://secwatch.observer/filing/0001185185-26-002273.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/dgac8k052926.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 8, 2024, X4 Pharmaceuticals, Inc. (the “Company”), entered into an asset purchase agreement (the “Asset Purchase Agreement”) to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”) for a lump sum payment of $105.0 million, payable in cash upon the closing of the sale, which occurred simultaneously with the parties entering into the Asset Purchase Agreement.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024021937/0001628280-24-021937-index.htm","comparable_excerpt":"A Share Rights Agreement, dated May 26, 2026, by and between the Company and Odyssey Transfer and Trust Company, as rights agent","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm"}},{"accession":"0001104659-26-068521","ticker":"FDXF","company_name":"FedEx Freight Holding Company, Inc.","filed_at":"2026-06-01T10:46:03+00:00","headline":"FedEx Freight completes spin-off from FedEx; $600M drawn, new board and executives appointed","event_type":"other_material","sec_items":["1.01","2.03","3.03","5.03","5.01","5.02","5.05","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: ma_transaction","same SEC item: 1.01, 5.02, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068521","json":"https://secwatch.observer/filing/0001104659-26-068521.json","markdown":"https://secwatch.observer/filing/0001104659-26-068521.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2082247/000110465926068521/0001104659-26-068521-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2082247/000110465926068521/tm2615735d2_8k.htm"},"side_by_side_evidence":{"fact_type":"ma_transaction","source_excerpt":"On May 8, 2024, X4 Pharmaceuticals, Inc. (the “Company”), entered into an asset purchase agreement (the “Asset Purchase Agreement”) to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”) for a lump sum payment of $105.0 million, payable in cash upon the closing of the sale, which occurred simultaneously with the parties entering into the Asset Purchase Agreement.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024021937/0001628280-24-021937-index.htm","comparable_excerpt":"On June 1, 2026, FedEx Freight Holding Company, Inc., a Delaware corporation (“FedEx Freight” or the “Company”) completed its spin-off from FedEx Corporation, a Delaware corporation (“FedEx”), into a new, publicly traded company (the “Spin-Off”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2082247/000110465926068521/0001104659-26-068521-index.htm"}},{"accession":"0001437749-26-017528","ticker":"DMRC","company_name":"Digimarc CORP","filed_at":"2026-05-18T12:50:44+00:00","headline":"Digimarc completes Reorganization; shares exchanged 1:1 for Digimarc Parent, Inc. stock","event_type":"other_material","sec_items":["2.01","3.03","5.01","5.02","8.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: ma_transaction","same SEC item: 2.01, 5.02, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-017528","json":"https://secwatch.observer/filing/0001437749-26-017528.json","markdown":"https://secwatch.observer/filing/0001437749-26-017528.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438231/000143774926017528/0001437749-26-017528-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438231/000143774926017528/dmrc20260427c_8k.htm"},"side_by_side_evidence":{"fact_type":"ma_transaction","source_excerpt":"On May 8, 2024, X4 Pharmaceuticals, Inc. (the “Company”), entered into an asset purchase agreement (the “Asset Purchase Agreement”) to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”) for a lump sum payment of $105.0 million, payable in cash upon the closing of the sale, which occurred simultaneously with the parties entering into the Asset Purchase Agreement.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024021937/0001628280-24-021937-index.htm","comparable_excerpt":"On May 15, 2026, Digimarc Corporation (the “Company”) completed its previously announced Reorganization (as defined below) pursuant to the Agreement and Plan of Reorganization (the “Agreement and Plan of Reorganization”), dated as of March 12, 2026, including the Agreement and Plan of Merger attached thereto (the “Merger Agreement” and, together with the Agreement and Plan of Reorganization, the “Reorganization Agreement”), dated as of March 12, 2026, by and among the Company, Digimarc Parent, Inc. (f/k/a Deschutes Parent, Inc.), an Oregon corporation (“Holdings”), and Deschutes Merger Sub, Inc., an Oregon corporation and, as of immediately prior to the consummation of the Reorganization, a wholly owned subsidiary of Holdings (“Merger Sub”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1438231/000143774926017528/0001437749-26-017528-index.htm"}},{"accession":"0001999371-26-011900","ticker":null,"company_name":"CNL Strategic Capital, LLC","filed_at":"2026-06-02T20:04:39+00:00","headline":"Shareholders reject enhanced liquidity plan (25% repurchase); loan amended for equity buybacks","event_type":"other_material","sec_items":["1.01","2.03","5.07","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-26-011900","json":"https://secwatch.observer/filing/0001999371-26-011900.json","markdown":"https://secwatch.observer/filing/0001999371-26-011900.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1684682/000199937126011900/0001999371-26-011900-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1684682/000199937126011900/cnl-8k_052726.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 8, 2024, X4 Pharmaceuticals, Inc. (the “Company”), entered into an asset purchase agreement (the “Asset Purchase Agreement”) to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”) for a lump sum payment of $105.0 million, payable in cash upon the closing of the sale, which occurred simultaneously with the parties entering into the Asset Purchase Agreement.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024021937/0001628280-24-021937-index.htm","comparable_excerpt":"On May 29, 2026, CNL Strategic Capital B, Inc. (the “Borrower”), a wholly-owned subsidiary of CNL Strategic Capital, LLC (the “Company”), and Valley National Bank, a Tennessee banking corporation (referred to as “Valley National Bank”), entered into a Third Amendment (the “Third Amendment”) to the Loan and Security Agreement, as amended (the “Loan Agreement”), previously entered into by such parties for a $50.0 million revolving line of credit (the “Line of Credit”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1684682/000199937126011900/0001999371-26-011900-index.htm"}},{"accession":"0001193125-26-252718","ticker":"QMCO","company_name":"QUANTUM CORP /DE/","filed_at":"2026-06-02T14:41:23+00:00","headline":"Quantum raises $100M equity, converts all convertible notes to equity; Q4 revenue above guidance","event_type":"other_material","sec_items":["1.01","2.02","2.03","3.02","8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-252718","json":"https://secwatch.observer/filing/0001193125-26-252718.json","markdown":"https://secwatch.observer/filing/0001193125-26-252718.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/709283/000119312526252718/0001193125-26-252718-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/709283/000119312526252718/d35173d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 8, 2024, X4 Pharmaceuticals, Inc. (the “Company”), entered into an asset purchase agreement (the “Asset Purchase Agreement”) to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”) for a lump sum payment of $105.0 million, payable in cash upon the closing of the sale, which occurred simultaneously with the parties entering into the Asset Purchase Agreement.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024021937/0001628280-24-021937-index.htm","comparable_excerpt":"In connection with the Private Placement, the Company entered into Registration Rights Agreements with the Investors, dated as of June 1, 2026 (the “PIPE Registration Rights Agreement”), pursuant to which the Company has agreed to (i) prepare and file a registration statement with the Securities and Exchange Commission (the “SEC”) covering the resale of the Common Stock sold in the Private Placement within 45 days of the closing of the Private Placement, (ii) use commercially reasonable efforts to have such registration statement declared effective within the time period set forth in the PIPE Registration Rights Agreement, and to keep such registration statement effective until the date that all registrable securities covered by such registration statement (a) have been sold, thereunder or pursuant to Rule 144, or (b) may be sold without volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for 1 the Company to be in compliance with the current public i","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/709283/000119312526252718/0001193125-26-252718-index.htm"}},{"accession":"0001213900-26-063832","ticker":"USAR","company_name":"USA Rare Earth, Inc.","filed_at":"2026-06-02T13:14:30+00:00","headline":"USA Rare Earth selects South Carolina for $1.2B magnet facility; 490 jobs, 6,400 tpa capacity","event_type":"other_material","sec_items":["1.01","2.03","7.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063832","json":"https://secwatch.observer/filing/0001213900-26-063832.json","markdown":"https://secwatch.observer/filing/0001213900-26-063832.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1970622/000121390026063832/0001213900-26-063832-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1970622/000121390026063832/ea0293127-8k_usarare.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 8, 2024, X4 Pharmaceuticals, Inc. (the “Company”), entered into an asset purchase agreement (the “Asset Purchase Agreement”) to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”) for a lump sum payment of $105.0 million, payable in cash upon the closing of the sale, which occurred simultaneously with the parties entering into the Asset Purchase Agreement.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024021937/0001628280-24-021937-index.htm","comparable_excerpt":"On June 1, 2026, USA Rare Earth, Inc. (the “Company”) entered into a Lease Agreement (the “Lease”) with TC Liberty Development, LLC, a Delaware limited liability company (“Landlord”), for the lease of a to-be-constructed specialty rare earth magnet manufacturing facility located on Bear Den Road in Blacksburg, Cherokee County, South Carolina (the “Premises”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1970622/000121390026063832/0001213900-26-063832-index.htm"}},{"accession":"0001213900-26-063565","ticker":"AIB","company_name":"BlockchAIn Digital Infrastructure, Inc.","filed_at":"2026-06-01T20:57:13+00:00","headline":"Blockchain Digital signs 15-yr, 65 MW electric agreement at CLT-01; 25 MW LOIs in pipeline","event_type":"other_material","sec_items":["1.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063565","json":"https://secwatch.observer/filing/0001213900-26-063565.json","markdown":"https://secwatch.observer/filing/0001213900-26-063565.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2070542/000121390026063565/0001213900-26-063565-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2070542/000121390026063565/ea0292328-8k_blockchain.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 8, 2024, X4 Pharmaceuticals, Inc. (the “Company”), entered into an asset purchase agreement (the “Asset Purchase Agreement”) to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”) for a lump sum payment of $105.0 million, payable in cash upon the closing of the sale, which occurred simultaneously with the parties entering into the Asset Purchase Agreement.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024021937/0001628280-24-021937-index.htm","comparable_excerpt":"On May 27, 2026, One Blockchain, LLC, a subsidiary of BlockchAIn Digital Infrastructure, Inc. (the “Company”) entered into a 15-year Electric Service Agreement (“Electric Service Agreement”) with a local utility provider (the “Utility Company”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2070542/000121390026063565/0001213900-26-063565-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}